{"id":"NCT02614183","sponsor":"Eli Lilly and Company","briefTitle":"Evaluation of Galcanezumab in the Prevention of Episodic Migraine- the EVOLVE-1 Study","officialTitle":"A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 in Patients With Episodic Migraine - the EVOLVE-1 Study","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-11-30","primaryCompletion":"2017-03-22","completion":"2018-08-09","firstPosted":"2015-11-25","resultsPosted":"2018-11-29","lastUpdate":"2020-06-17"},"enrollment":862,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Migraine"],"interventions":[{"type":"DRUG","name":"Galcanezumab","otherNames":["LY2951742"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Galcanezumab 120mg","type":"EXPERIMENTAL"},{"label":"Galcanezumab 240mg","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The main purpose of this study is to evaluate the efficacy of the study drug known as galcanezumab in participants with episodic migraine.","primaryOutcome":{"measure":"Overall Mean Change From Baseline in the Number of Monthly Migraine Headache Days","timeFrame":"Baseline, Month 1 through Month 6","effectByArm":[{"arm":"Placebo","deltaMin":-2.81,"sd":0.24},{"arm":"Galcanezumab 120mg","deltaMin":-4.73,"sd":0.29},{"arm":"Galcanezumab 240mg","deltaMin":-4.57,"sd":0.29}],"pValues":[{"comp":"OG000 vs OG001","p":"<.001"},{"comp":"OG000 vs OG002","p":"<.001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":1,"exclusionCount":4},"locations":{"siteCount":95,"countries":["United States","Canada","Puerto Rico"]},"refs":{"pmids":["35076090","34264500","34049484","33950375","33549036","33544305","33143451","33069214","32576229","31952501","31482569","31253091","30942898","30594122","30462830","29813147"],"seeAlso":["http://www.lillytrialguide.com/EN-us/studies/headache/cgag"]},"adverseEventsSummary":{"seriousAny":{"events":5,"n":432},"commonTop":["Injection site pain","Upper respiratory tract infection","Viral upper respiratory tract infection","Urinary tract infection","Injection site reaction"]}}